The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

The Dementia Discovery Fund ("DDF"), managed by SV Health Investors, today announced the final closing of its second fund, DDF-2, with $269m in commitments. DDF is the world's largest family of ...

Pfizer just penned a $6 billion licensing deal with China's 3SBio to develop and commercialize a cancer drug, SSGJ-707. The ...

David Rhew, MD, global chief medical officer and VP of ... such as CVS, expanding partnerships have become necessary for their digital progression. Boosted by Microsoft's offerings, CVS intends ...

Pfizer and BioNTech said their alliance aims to develop an "improved" vaccine for shingles, and marks their third partnership in ... easily scalable to support global access," he added.

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...